arrow
G

Guillaume Morcrette

institut national de la santé et de la recherche médicale (inserm)
H指数:13
被引数:1,687

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Targeting ATR to overcome cisplatin resistance in hepatoblastoma

靶向ATR以克服肝母细胞瘤对顺铂的耐药性

2025-11-290
PRE
Multi-Observer Study on Diagnostic Accuracy of Pediatric Renal Tumors Imaged with Higher-Harmonic-Generation Microscopy

多观察者研究:高谐波生成显微镜成像的儿科肾肿瘤诊断准确性

CANCERS
IF4.4
2025-05-180
OA
Somatic genetic development of Wilms tumor via normal kidneys in predisposed children

易感儿童通过正常肾脏进行Wilms肿瘤的体细胞遗传发育

2024-09-050
PRE
Single-cell multiomics reveals the interplay of clonal evolution and cellular plasticity in hepatoblastoma
2024-04-084
OAAI
Mutational signature, cancer driver genes mutations and transcriptomic subgroups predict hepatoblastoma survival
2024-03-010
OA
Preneoplastic liver colonization by 11p15.5 altered mosaic cells in young children with hepatoblastoma

11 p15.5改变的镶嵌细胞在肝母细胞瘤幼儿中的肿瘤前肝脏定植

2023-11-062
OAAI
Targetable NOTCH1 rearrangements in reninoma
2023-09-251
OAAI
Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target (vol 74, pg 1155, 2021)
2022-05-010
OA
Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target

端粒长度是肝细胞癌多样性的关键,端粒酶成瘾是可行的治疗靶点

2021-05-0165
OAAI
Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver Cancer

整合基因组分析确定小儿肝癌的驱动基因和顺铂耐药祖细胞表型

2021-04-2326
OA
BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA (vol 72, pg 924, 2020)
2020-07-010
OAAI
Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma
2019-08-12148
PREAI
Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation
2017-03-01273
OAAI
NOSOLOGY AND MOLECULAR CLASSIFICATION OF HEPATOCELLULAR ADENOMAS
2016-01-012
PREAI